sitemap

Crown Bioscience, one of CID Fund III portfolios, was sucessfully transferred from Emerging Board of Taipei Exchange to the Main Board

Dec 12, 2016

Headquartered in Silicon Valley with research facilities in the United States, United Kingdom, mainland China and Taiwan, the Company provides cutting-edge translational platforms helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. With the world's largest commercial collection of validated Patient-Derived Xenograft (PDX) models, the company can help the biopharmaceutical clients accelerate their new drug development programs significantly.

Read more X

Suceessfully listed on China's National Equities, Transn is a leading multi-language translation service provider in China

Mar 3, 2016

The CID Group (“CID”) is pleased to announce the successful listing of “Transn (China) Technology Co.,Ltd (“Transn”), on China’s National Equities Exchange and Quotations (NEEQ), known as “New Third Board” (Stock Code: 835737.NE) on February 29th, 2016.

Read more X

Crown Bio, a leading global drug discovery and preclinical development service company, was sucessfully listed on Emerging Stock Market of Taipei Exchange

Feb 18, 2016

The CID Group (“CID”) is pleased to announce the successful listing of Crown Bioscience Ltd. (“Crown Bio” or “the Company”), one of CID Greater China Venture Capital Fund III, L.P.’s (“Fund”) portfolio companies, on the Emerging Stock Market of Taipei Exchange (Stock Code: 6554 TT) on February 18th, 2016.

Read more X